Update in the Epidemiology, Prophylaxis, and Treatment of Fungal Infections in Patients with Hematologic Disorders

References

• Laverdiere, M., Rotstein, C., Bow, E.J., Roberts, R.S., Ioannou, S., Carr, D., et al. (2000) "Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study", J. Antimicrob. Chemother., 46, 1001 —1008.
   Web of Science ®Google Scholar
• Martino, P., Girmenia, C., Micozzi, A., De Bernardis, F., Boccanera, M. and Cassone, A. (1994) "Prospective study of Candida colonization, use of empiric amphotericin B and development of invasive mycosis in neutropenic patients", Eur. J. Clin. Microbiol. Infect. Dis., 13, 797–804.
   Google Scholar
• Pittet, D., Monod, M., Suter, P.M., Frenk, E. and Auckenthaler, R. (1994) "Candida colonization and subsequent infections in critically ill surgical patients", Ann. Surg., 220, 751–758.
   Web of Science ®Google Scholar
• Girmenia, C. and Martino, P. (1998) "Fluconazole and the changing epidemiology of candidemia", Clin. Infect. Dis., 27, 232— 234.
   Google Scholar
• Weems, ii., Jr., Davis, B.J., TabIan, O.C., Kaufman, L. and Martone, W.J. (1987) "Construction activity: an independent risk factor for invasive aspergillosis and zygomycosis in patients with hematologic malignancy", Infect Control, 8, 71–75.
   PubMedGoogle Scholar
• Krasinski, K., Holzman, R.S., Hanna, B., Greco, M.A., Graff, M. and Bhogal, M. (1985) "Nosocomial fungal infection during hospital renovation", Infect Control, 6, 278 — 282.
   Web of Science ®Google Scholar
• Sarubbi, F.A., Jr., Kopf, H.B., Wilson, MB., McGinnis, M.R. and Rutala, W.A. (1982) "Increased recovery of Aspergillus flavus from respiratory specimens during hospital construction", Am. Rev. Respir. Dis., 125, 33–38.
   PubMed Web of Science ®Google Scholar
• Anaissie, E.J., Stratton, S.L., Dignani, MC., Lee, C.K., Summer-bell, R.C., Rex, J.H., et al. (2003) "Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies", Blood, 101, 2542–2546.
   PubMed Web of Science ®Google Scholar
• Anaissie, E.J. and Costa, S.F. (2001) "Nosocomial aspergillosis is waterborne", Clin. Infect. Dis., 33, 1546 — 1548.
   Google Scholar
• Warns, A., Voss, A., Abrahamsen, T.G. and Verweij, P.E. (2002) "Contamination of hospital water with Aspergillus fumigatus and other molds", Clin. Infect. Dis., 34, 1159–1160.
   Google Scholar
• Groll, A.H., Shah, P.M., Mentzel, C., Schneider, M., Just-Nuebling, G. and Huebner, K. (1996) "Trends in the postmortem epidemiology of invasive fungal infections at a university hospital", J. Infect., 33, 23 — 32.
   PubMed Web of Science ®Google Scholar
• Viscoli, C., Girmenia, C., Marinus, A., Collette, L., Martino, P., Vandercam, B., et al. (1999) "Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)", Clin. Infect. Dis., 28, 1071 — 1079.
   Google Scholar
• Rotstein, C., Bow, E.J., Laverdiere, M., Ioannou, S., Carr, D. and Moghaddam, N. (1999) "Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group", Clin. Infect. Dis., 28, 331— 340.
   Google Scholar
• Kanda, Y., Yamamoto, R., Chizuka, A., Hamaki, T., Suguro, M., Arai, C., et al. (2000) "Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials", Cancer, 89, 1611— 1625.
   Web of Science ®Google Scholar
• Bow, E.J., Laverdiere, M., Lussier, N., Rotstein, C., Cheang, M.S. and Ioannou, S. (2002) "Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of rando-mized-controlled clinical trials", Cancer, 94, 3230— 3246.
   Google Scholar
• Passweg, J.R., Rowlings, PA., Atkinson, K.A., Barrett, A.J., Gale, R.P., Gratwohl, A., et al. (1998) "Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia", Bone Marrow Transplant., 21, 1231–1238.
   PubMed Web of Science ®Google Scholar
• Fukuda, T., Boeckh, M., Carter, R.A., Sandmaier, B.M., Mans, M.B., Maloney, D.G., et al. (2003) "Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning", Blood, 102, 827–833.
   Google Scholar
• Marr, K.A., Carter, R.A., Crippa, F., Wald, A. and Corey, L. (2002) "Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients", Clin. Infect. Dis., 34, 909–917.
   Google Scholar
• Jantunen, E., Ruutu, P., Niskanen, L., Volin, L., Parkkali, T., Koukila-Kahkola, P., et al. (1997) "Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients", Bone Marrow Transplant., 19, 801–808.
   PubMed Web of Science ®Google Scholar
• Baddley, J.W., Stroud, T.P., Salzman, D. and Pappas, P.G. (2001) "Invasive mold infections in allogeneic bone marrow transplant recipients", Clin. Infect. Dis., 32, 1319 — 1324.
   Google Scholar
• Martino, R., Subira, M., Rovira, M., Solano, C., Vazquez, L., Sanz, G.F., et al. (2002) "Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients", Br. J. HaematoL, 116, 475–482.
   Web of Science ®Google Scholar
• Grow, W.B., Moreb, JS., Roque, D., Manion, K., Leather, H., Reddy, V., et al. (2002) "Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital", Bone Marrow Transplant., 29, 15 — 19.
   Google Scholar
• van Bunk, J.H., Leisenring, W., Myerson, D., Hackman, R.C., Shulman, H.M., Sale, G.E., et al. (1998) "The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients", Medicine (Baltimore), 77, 246–254.
   PubMed Web of Science ®Google Scholar
• Marr, K.A., Seidel, K., White, T.C. and Bowden, R.A. (2000) "Candidemia in allogeneic blood and marrow transplant recipi-ents: evolution of risk factors after the adoption of prophylactic fluconazole", J. Infect. Dis., 181, 309 — 316.
   Google Scholar
• Trick, W.E., Fridkin, S.K., Edwards, J.R., Hajjeh, R.A. and Gaynes, R.P. (2002) "Secular trend of hospital-acquired candide-mia among intensive care unit patients in the United States during 1989-1999", Clin. Infect. Dis., 35, 627–630.
   Google Scholar
• Pfaller, M.A., Diekema, D.J., Jones, R.N., Messer, S.A. and Hollis, R.J. (2002) "Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000", J. Clin. Microbiol., 40, 852–856.
   Web of Science ®Google Scholar
• Levin, AS., Costa, S.F., Mussi, N.S., Basso, M., Sinto, S.I., Machado, C., et al. (1998) "Candida parapsilosis fungemia associated with implantable and semi-implantable central venous catheters and the hands of healthcare workers", Diagn. Microbiol. Infect. Dis., 30, 243–249.
   Google Scholar
• Lin, Si., Schranz, J. and Teutsch, S.M. (2001) "Aspergillosis case-fatality rate: systematic review of the literature", Clin. Infect. Dis., 32, 358 — 366.
   Google Scholar
• Mann, K.A., Carter, R.A., Boeckh, M., Martin, P. and Corey, L. (2002) "Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors", Blood, 100, 4358–4366.
   Google Scholar
• Wald, A., Leisenring, W., van Burik, J.A. and Bowden, R.A. (1997) "Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation", J. Infect. Dis., 175, 1459 — 1466.
   Google Scholar
• Saugier-Veber, P., Devergie, A., Sulahian, A., Ribaud, P., Traore, F., Bourdeau-Esperou, H., et al. (1993) "Epidemiology and diagnosis of invasive pulmonary aspergillosis in bone marrow transplant patients: results of a 5 year retrospective study", Bone Marrow Transplant., 12, 121 — 124.
   Google Scholar
• Lewis, R.E., Torres, H.A., May, G.S., Raad, II., Thornby, J., Rolston, K.V.I., et al. (2002) [M-1491] In vitro susceptibility and tolerance of Aspergillus species (spp) in a tertiary care center: correlation with invasive aspergillosis (IA) and its outcome. San Diego: ICAAC.
   Google Scholar
• Walsh, T.J., Roden, M., Nelson, L., Knudson, T., Venzon, D., Segal, B., et al. (2002) [M-1233] Invasive fungal infections complicating non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT). San Diego: ICAAC.
   Google Scholar
• Ascioglu, S., Rex, J.H., de Pauw, B., Bennett, J.E., Bille, J., Crokaert, F., et al. (2002) "Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus", Clin. Infect. Dis., 34, 7 — 14.
   Google Scholar
• Chumpitazi, B.F., Pinel, C., Lebeau, B., Ambroise-Thomas, P. and Grillot, R. (2000) "Aspergillus fumigatus antigen detection in sera from patients at risk for invasive aspergillosis", J. Clin. Microbiol., 38, 438–443.
   Web of Science ®Google Scholar
• Maertens, J., Verhaegen, J., Lagrou, K., Van Eldere, J. and Boogaerts, M. (2001) "Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation", Blood, 97, 1604–1610.
   PubMed Web of Science ®Google Scholar
• Verweij, P.E., Poulain, D., Obayashi, T., Patterson, T.F., Denning, D.W. and Ponton, J. (1998) "Current trends in the detection of antigenaemia, metabolites and cell wall markers for the diagnosis and therapeutic monitoring of fungal infections", Med. MycoL, 36 Suppl 1, 146–155.
   Google Scholar
• Maertens, J., Verhaegen, J., Demuynck, H., Brock, P., Verhoef, G., Vandenberghe, P., et al. (1999) "Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis", J. Clin. Microbiol., 37, 3223–3228.
   Web of Science ®Google Scholar
• Herbrecht, R., Letscher-Bru, V., Oprea, C., Lioure, B., Waller, J., Campos, F., et al. (2002) "Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients", J. Clin. Oncol., 20, 1898 — 1906.
   PubMed Web of Science ®Google Scholar
• Pinel, C., Fricker-Hidalgo, H., Lebeau, B., Garban, F., Hamidfar, R., Ambroise-Thomas, P., et al. (2003) "Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the platelia test for diagnosing invasive aspergillosis", J. Clin. Microbiol., 41, 2184–2186.
   PubMed Web of Science ®Google Scholar
• Odabasi, Z., Mattiuzzi, G., Ostrosky-Zeichner, L., Estey, E., Kantarjian, H. and Rex, J.H. (2002) [M-902] Detection of (1,3)-/3-D-glucan (BG) in the serum of leukemia patients (pts) with invasive fungal infections (IFI). San Diego: ICAAC.
   Google Scholar
• Lin, MT., Lu, H.C. and Chen, W.L. (2001) "Improving efficacy of antifungal therapy by polymerase chain reaction-based strategy among febrile patients with neutropenia and cancer", Clin. Infect. Dis., 33, 1621–1627.
   Web of Science ®Google Scholar
• Einsele, H., Hebart, H., Roller, G., Loftier, J., Rothenhofer, I., Muller, CA., et al. (1997) "Detection and identification of fungal pathogens in blood by using molecular probes", J. Clin. Microbiol., 35, 1353 — 1360.
   Web of Science ®Google Scholar
• Rex, J.H., Pfaller, M.A., Walsh, Ti., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, MA., et al. (2001) "Antifungal suscept-ibility testing: practical aspects and current challenges", Clin. Microbiol. Rev., 14, 643–658.
   PubMed Web of Science ®Google Scholar
• Arthington-Skaggs, BA., Lee-Yang, W., Ciblak, MA., Frade, J.P., Brandt, ME., Hajjeh, R.A., et al. (2002) "Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates", Antimicrob. Agents Chemother., 46, 2477–2481.
   PubMed Web of Science ®Google Scholar
• Hawser, S.P., Jessup, C., Vitullo, J. and Ghannoum, MA. (2001) "Utility of 2,3-bis(2-methoxy-4-nitro-5-sulfopheny1)-5-[(phenyl-amino)carbonyl]-2H-tet razolium hydroxide (XTT) and minimum effective concentration assays in the determination of antifungal susceptibility of Aspergillus fumigatus to the lipopeptide class compounds", J. Clin. Microbiol., 39, 2738–2741.
   Web of Science ®Google Scholar
• Balajee, S.A. and Mann, K.A. (2002) "Conidial viability assay for rapid susceptibility testing of Aspergillus species", J. Clin. Microbiol., 40, 2741 —2745.
   Web of Science ®Google Scholar
• Arthington-Skaggs, B.A., Warnock, D.W. and Morrison, C.J. (2000) "Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis", Antimicrob. Agents Che-mother., 44, 2081 —2085.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis, D.P. and Lewis, RE. (2002) "Antifungal drug resistance of pathogenic fungi", Lancet, 359, 1135–1144.
   Google Scholar
• Balkis, MM., Leidich, S.D., Mukherjee, P.K. and Ghannoum, MA. (2002) "Mechanisms of fungal resistance: an overview", Drugs, 62, 1025–1040.
   Google Scholar
• Woolley, I., Curtis, D., Szer, J., Fairley, C., Vujovic, O., Ugoni, A., et al. (1997) "High dose cytosine arabinoside is a major risk factor for the development of hepatosplenic candidiasis in patients with leukemia", Leuk. Lymphoma, 27, 469–474.
   PubMed Web of Science ®Google Scholar
• Gerson, S.L., Talbot, G.H., Hurwitz, S., Strom, B.L., Lusk, E.J. and Cassileth, P.A. (1984) "Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia", Ann. Intern. Med., 100, 345 — 351.
   Web of Science ®Google Scholar
• Segal, B.H., Bow, E.J. and Menichetti, F. (2002) "Fungal infections in nontransplant patients with hematologic malignancies", Infect. Dis. Clin. North Am., 16, 935–964, vii.
   Google Scholar
• Ng, T.T., Robson, G.D. and Denning, D.W. (1994) "Hydrocorti-sone-enhanced growth of Aspergillus spp.: implications for pathogenesis", Microbiology, 140, 2475–2479.
   Google Scholar
• Klepser, ME., Wolfe, E.J., Jones, RN., Nightingale, C.H. and Pfaller, M.A. (1997) "Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans", Antimicrob. Agents Chemother., 41, 1392— 1395.
   PubMed Web of Science ®Google Scholar
• Andes, D., Stamsted, T. and Conklin, R. (2001) "Pharmacody-namics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model", Antimicrob. Agents Chemother., 45, 922–926.
   PubMed Web of Science ®Google Scholar
• Prentice, HG., Hann, TM., Herbrecht, R., Aoun, M., Kvaloy, S., Catovsky, D., et al. (1997) "A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients", Br. J. Haematol., 98, 711 — 718.
   Web of Science ®Google Scholar
• Walsh, Ti., Finberg, R.W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., et al. (1999) "Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group", N. Engl. J. Med., 340, 764–771.
   Google Scholar
• Leenders, AC., Daenen, S., Jansen, R.L., Hop, W.C., Lowenberg, B., Wijermans, P.W., et al. (1998) "Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections", Br. J. Haematol., 103, 205–212.
   Web of Science ®Google Scholar
• Leenders, AC., Reiss, P., Portegies, P., Clezy, K., Hop, W.C., Hoy, J., et al. (1997) "Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis", Aids, 11, 1463–1471.
   Google Scholar
• Bowden, R., Chandrasekar, P., White, M.H., Li, X., Pietrelli, L., Gurwith, M., et al. (2002) "A double-blind, randomized, con-trolled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immuno-compromised patients", Clin. Infect. Dis., 35, 359–366.
   Google Scholar
• Johnson, P.C., Wheat, L.J., Cloud, GA., Goldman, M., Lancaster, D., Bamberger, D.M., et al. (2002) "Safety and efficacy of liposomal amphotericin B compared with conventional amphoter-icin B for induction therapy of histoplasmosis in patients with AIDS", Ann. Intern. Med., 137, 105 — 109.
   Web of Science ®Google Scholar
• Wingard, J.R. (2002) "Lipid formulations of amphotericins: are you a lumper or a splitter?", Clin. Infect. Dis., 35, 891–895.
   Web of Science ®Google Scholar
• Ringden, O., Meunier, F., Tollemar, J., Ricci, P., Tura, S., Kuse, E., etal. (1991) "Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients", J. Antimicrob. Chemother., 28, 73–82.
   PubMed Web of Science ®Google Scholar
• Walsh, Ti., Hiemenz, J.W., Seibel, N.L., Perfect, J.R., Horwith, G., Lee, L., et al. (1998) "Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases", Clin. Infect. Dis., 26, 1383–1396.
   Google Scholar
• White, M.H., Anaissie, E.J., Kusne, S., Wingard, J.R., Hiemenz, J.W., Cantor, A., et al. (1997) "Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillo-sis", Clin. Infect. Dis., 24, 635–642.
   Google Scholar
• Cagnoni, P.J., Walsh, Ti., Prendergast, MM., Bodensteiner, D., Hiemenz, S., Greenberg, RN., et al. (2000) "Pharmacoeconomic analysis of liposomal amphotericin B versus conventional ampho-tericin B in the empirical treatment of persistently febrile neutropenic patients", J. Clin. Oncol., 18, 2476–2483.
   Web of Science ®Google Scholar
• Wingard, J.R., Kubilis, P., Lee, L., Yee, G., White, M., Walshe, L., et al. (1999) "Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis", Clin. Infect. Dis., 29, 1402 — 1407.
   Google Scholar
• Micromedex Healthcare Series. Vol. 2003: Thomson.
   Google Scholar
• Marr, K.A. (2002) Infections in Transplant Patients. San Diego: ICAAC.
   Google Scholar
• Gangwar, M., Doney, A., Cole, R., Sheehan, DJ. and Chaturvedi, V. (2002) [M-216] Study of Aspergillus fumigatus-Antifungal interactions by fluorescent probes & image analysis. San Diego: ICAAC.
   Google Scholar
• Johnson, L.B. and Kauffman, CA. (2003) "Voriconazole: a new triazole antifungal agent", Clin. Infect. Dis., 36, 630–637.
   Google Scholar
• Vfend prescribing information. Vol. 2002: Pfizer.
   Google Scholar
• Pfaller, M.A., Messer, S.A., Hollis, R.J. and Jones, RN. (2002) "Antifungal activities of posaconazole, ravuconazole, and vorico-nazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveil-lance Program, 2000", Antimicrob. Agents Chemother., 46, 1032 — 1037.
   PubMed Web of Science ®Google Scholar
• Pfaller, M.A., Messer, S.A., Hollis, R.J., Jones, RN. and Diekema, D.J. (2002) "In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.", Antimicrob. Agents Chemother., 46, 1723–1727.
   PubMed Web of Science ®Google Scholar
• Abruzzo, G.K., Flattery, AM., Gill, C.J., Kong, L., Smith, J.G., Pikounis, V.B., et al. (1997) "Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis", Anti-microb. Agents Chemother., 41, 2333–2338.
   PubMed Web of Science ®Google Scholar
• Cancidas prescribing information. Vol. 2002: Merck.
   Google Scholar
• Goodman, J.L., Winston, D.J., Greenfield, R.A., Chandrasekar, PH., Fox, B., Kaizer, H., et al. (1992) "A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation", N. Engl. J. Med., 326, 845–851.
   Google Scholar
• Slavin, MA., Osborne, B., Adams, R., Levenstein, M.J., Schoch, HG., Feldman, AR., et al. (1995) "Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation— a prospective, randomized, double-blind study", J. Infect. Dis., 171, 1545–1552.
   Google Scholar
• MacMillan, ML., Goodman, J.L., DeFor, T.E. and Weisdorf, D.J. (2002) "Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy", Am. J. Med., 112, 369–379.
   Google Scholar
• Johansen, H.K. and Gotzsche, P.C. (2002) "Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients", Cochrane Database of Systematic Reviews, 3, CD000239.
   Google Scholar
• Gotzsche, P.C. and Johansen, H.K. (2002) "Routine versus selective antifungal administration for control of fungal infections in patients with cancer", Cochrane Database Syst Rev, CD000026.
   Google Scholar
• Comely, O.A., Ullmann, A.J. and Karthaus, M. (2003) "Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies", Blood, 101, 3365–3372.
   Google Scholar
• Morgenstern, G.R., Prentice, AG., Prentice, HG., Ropner, J.E., Schey, S.A. and Warnock, D.W. (1999) "A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group", Br. J. Haema-tol., 105, 901 — 911.
   PubMed Web of Science ®Google Scholar
• Winston, D.J., Maziarz, R.T., Chandrasekar, PH., Lazarus, H.M., Goldman, M., Blumer, J.L., et al. (2003) "Intravenous and Oral Itraconazole versus Intravenous and Oral Fluconazole for Long-Term Antifungal Prophylaxis in Allogeneic Hematopoietic Stem-Cell Transplant Recipients. A Multicenter, Randomized Trial", Ann. Intern. Med., 138, 705–713.
   Web of Science ®Google Scholar
• Marr, K.A., Crippa, F., Leisenring, W., Hoyle, M., Boeckh, M., Balajee, A., et al. (2003) "Itraconazole versus fluconazole for prevention of fungal infections in allogeneic stem cell transplant patients", Blood, DOI 10.1182/blood-2003-08-2644. Pre-published October 2, 2003. http://www.bloodjournal.org/cgi/reprint/2003-08-2644v1.pdf
   Google Scholar
• van Bunk, J., Ratanatharathorn, V., Lipton, J., Miller, C., Bunin, N. and Walsh, T.J. (2002) [M-1238] Randomized, double-blind trial of micafungin (MI) versus fluconazole (FL) for prophylaxis of invasive fungal infections in patients (pts) undergoing hematopoietic stem cell transplant (HSCT), NIAID/BAMSG protocol 46. San Diego: ICAAC.
   Google Scholar
• Offner, F., Cordonnier, C., Ljungman, P., Prentice, H.G., En-gelhard, D., De Bacquer, D., et al. (1998) "Impact of previous aspergillosis on the outcome of bone marrow transplantation", Clin. Infect. Dis., 26, 1098–1103.
   PubMed Web of Science ®Google Scholar
• Cordonnier, C., Pautas, C., Bastie, J., Castaigne, S., Maury, S., Bretagne, S., etal. (2002) Voriconazole as secondary prophylaxis for leukemic patients with previous invasive fungal diseases and going to a new at-risk phase. San Diego: ICAAC.
   Google Scholar
• De Pauw, B.E., Deresinski, S.C., Feld, R., Lane-Allman, E.F. and Donnelly, J.P. (1994) "Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group", Ann. Intern. Med., 120, 834 — 844.
   Web of Science ®Google Scholar
• Pizzo, P.A., Robichaud, K.J., Gill, F.A. and Witebsky, F.G. (1982) "Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia", Am. J. Med., 72, 101 — 1 1 1.
   Google Scholar
• EORTC International Antimicrobial Therapy Cooperative Group(1989) "Empiric antifungal therapy in febrile granulocyto-penic patients", Am. J. Med., 86, 668 — 672.
   Google Scholar
• Hughes, W.T., Armstrong, D., Bodey, G.P., Brown, A.E., Edwards, J.E., Feld, R., et al. (1997) "1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America", Clin. Infect. Dis., 25, 551–573.
   Google Scholar
• Boogaerts, M., Winston, D.J., Bow, E.J., Garber, G., Reboli, A.C., Schwarer, A.P., et al. (2001) "Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial", Ann. Intern. Med., 135, 412–422.
   Web of Science ®Google Scholar
• Walsh, Ti., Pappas, P., Winston, DJ., Lazarus, H.M., Petersen, F., Raffalli, J., et al. (2002) "Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever", N. Engl. J. Med., 346, 225–234.
   Google Scholar
• Herbrecht, R., Denning, D.W., Patterson, T.F., Bennett, J.E., Greene, R.E., Oestmann, J.W., et al. (2002) "Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis", N. Engl. J. Med., 347, 408 —415.
   Google Scholar
• Denning, D.W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., et al. (2002) "Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis", Chit Infect. Dis., 34, 563 — 571.
   Google Scholar
• Walsh, T.J., Lutsar, I., Driscoll, T., Dupont, B., Roden, M., Ghahramani, P., et al. (2002) "Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children", Pediatr. Infect. Dis. J., 21, 240–248.
   Google Scholar
• Denning, D.W. (1998) "Invasive aspergillosis", Clin. Infect. Dis., 26, 781–803; quiz 804–785.
   Google Scholar
• Maertens, J., Raad, I., Petrikkos, G., Selleslag, D., Petersen, F., Sable, C., et al. (2002) Update of the multicenter noncomparative study of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to other antifungal agents: analysis of 90 patients. San Diego: 42nd ICAAC.
   Google Scholar
• Sanz-Rodriguez, C., Aguado, J.M., Cisneros, J.M., Vivancos, R. and Gonzalez-Esteban, J. (2002) [M-895] Caspofungin therapy in documented fungal infections: Spanish experience before licensure of the drug. San Diego, CA: 42nd ICAAC.
   Google Scholar
• Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, AL., Thompson-Moya, L., Smietana, J., et al. (2002) "Comparison of caspofungin and amphotericin B for invasive candidiasis", N. Engl. J. Med., 347, 2020–2029.
   Web of Science ®Google Scholar
• Te Dorsthorst, D.T.A., Mouton, J.W., Van der Lee, H.A.L. and Verweij, P.E. (2002) [M-850] In vitro interactions of antifungals against clinical Aspergillus isolates. San Diego: ICAAC.
   Google Scholar
• Bachmann, S.P., Ramage, G., Fothergill, A.W., Rinaldi, M.G., Wickes, B.L., Patterson, T.F., etal. (2002) [M-1813] Combinations of antifungal agents against Candida albicans biofilms in vitro. San Diego: ICAAC.
   Google Scholar
• Thiebaut, A., Antal, D., Breysse, M.C. and Pivot, C. (2002) [M-859] Refractory invasive fungal infections in patients (pts) with hematologic malignancies: Combination of new antifungal agents (voriconazole or caspofungin) with amphotericin B. San Diego: ICAAC.
   Google Scholar
• Kontoyiannis, D.P., Hachem, R., Lewis, RE., Rivero, G., Kantarjian, H. and Raad, LI. (2002) [M-1820] Efficacy and toxicity of the caspofungin/liposomal amphotericin B (CASILipoAMB) combination in documented or possible invasive aspergillosis (IA) in patients (Pts) with hematologic malignancies. San Diego: ICAAC.
   Google Scholar
• Aliff, TB., Maslak, PG., Jurcic, J.G., Heaney, ML., Cathcart, K.N., Sepkowitz, K.A., et al. (2003) "Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin", Cancer, 97, 1025–1032.
   Google Scholar
• Perea, S., Gonzalez, G., Fothergill, A.W., Kirkpatrick, W.R., Rinaldi, M.G. and Patterson, T.F. (2002) "In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.", Ant imicrob. Agents Chem other., 46, 3039 — 3041.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick, W.R., Perea, S., Coco, B.J. and Patterson, T.F. (2002) "Efficacy of caspofungin alone and in combination with vorico-nazole in a Guinea pig model of invasive aspergillosis", Anti-microb. Agents Chemother., 46, 2564–2568.
   PubMed Web of Science ®Google Scholar
• Gentina, T., De Botton, S., Alfandari, S., Delomez, J., Jaillard, S., Leroy, O., et al. (2002) [M-860] Combination antifungals for treatment of pulmonary invasive aspergillosis (IA) refractory to amphotericin B (AmB) in leukaemia patients. San Diego: ICAAC.
   Google Scholar
• Rubin, MA., Carroll, K.C. and Cahill, B.C. (2002) "Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans", Clin. Infect. Dis., 34, 1160 — 1161.
   Google Scholar
• Kontoyiannis, D.P., Lewis, RE., May, G.S., Albert, N.D. and Raad, LI. (2002) [M-851] Sequential exposure of A. fumigatus to itraconazole (ITRA) and caspofungin (CAS): Evidence of enhanced in vitro activity of this combination. San Diego: ICAAC.
   Google Scholar
• Cacciapuoti, A.F., Gurnani, M., Halpern, J., Gheyas, F., Hare, R. and Loebenberg, D. (2002) [M-1814] Combination treatment of posaconazole (POS) and amphotericin B (AmB) against Candida albicans in a mouse systemic infection model. San Diego: ICAAC.
   Google Scholar
• Caillot, D., Casasnovas, O., Bernard, A., Couaillier, J.F., Durand, C., Cuisenier, B., et al. (1997) "Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery", J. Clin. Oncol., 15, 139 — 147.
   Web of Science ®Google Scholar
• Baron, O., Guillaume, B., Moreau, P., Germaud, P., Despins, P., De Lajartre, A.Y., et al. (1998) "Aggressive surgical management in localized pulmonary mycotic and nonmycotic infections for neutropenic patients with acute leukemia: report of eighteen cases", J. Thorac. Cardiovasc. Surg., 115, 63–68; discussion 68 — 69.
   Google Scholar
• Caillot, D., Couaillier, J.F., Bernard, A., Casasnovas, O., Denning, D.W., Mannone, L, et al. (2001) "Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutrope-nia", J. Clin. Oncol., 19, 253–259.
   Web of Science ®Google Scholar
• Hubel, K., Dale, D.C., Engert, A. and Liles, W.C. (2001) "Current status of granulocyte (neutrophil) transfusion therapy for infec-tious diseases", J. Infect. Dis., 183, 321–328.
   Google Scholar
• Bhatia, S., McCullough, J., Perry, E.H., Clay, M., Ramsay, N.K. and Neglia, J.P. (1994) "Granulocyte transfusions: efficacy in treating fungal infections in neutropenic patients following bone marrow transplantation", Transfusion, 34, 226–232.
   Google Scholar
• Price, T.H., Bowden, R.A., Boeckh, M., Bux, J., Nelson, K., Liles, W.C., etal. (2000) "Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplanta-tion", Blood, 95, 3302–3309.
   PubMed Web of Science ®Google Scholar
• Peters, C., Minkov, M., Matthes-Martin, S., Potschger, U., Witt, V., Mann, G., et al. (1999) "Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised neutropenic patients", Br. J. Haematol., 106, 689 — 696.
   Google Scholar
• Dignani, MC., Anaissie, E.J., Hester, J.P., O'Brien, S., Vartivar-ian, S.E., Rex, J.H., et al. (1997) "Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study", Leukemia, 11, 1621 — 1630.
   PubMed Web of Science ®Google Scholar